Stock Research: MedinCell

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

MedinCell

ENXTPA:MEDCL FR0004065605
27
  • Value
    4
  • Growth
    89
  • Safety
    Safety
    20
  • Combined
    14
  • Sentiment
    51
  • 360° View
    360° View
    27
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Medincell SA is a France-based manufacturer of biological products and pharmaceutical preparations. The company develops therapeutic solutions with worldwide access, collaborating with pharmaceutical corporations, physicians, biotechnology firms, academics, and foundations. Their main businesses include developing long-acting injectable medicines for various therapeutic areas such as schizophrenia, post-surgical pain and inflammation, contraception, and depression. In the last fiscal year, the company had a market cap of $622 million and revenue of $27 million.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 27 (better than 27% compared with alternatives), overall professional sentiment and financial characteristics for the stock MedinCell are below the industry average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for MedinCell. The consolidated Growth Rank has a good rank of 89, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 89% of competitors in the same industry. The consolidated Sentiment Rank also has a good rank of 51, which means that professional investors are more optimistic about the stock than for 51% of alternative investment opportunities. But the consolidated Value Rank has a less desirable rank of 20, which means that the share price of MedinCell is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 80% of alternative stocks in the same industry. Finally, the consolidated Safety Rank has a riskier rank of 4, which means that the company has a financing structure that is riskier than those of 96% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more

more
Index
CAC All
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 2-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
20 22 41 56
Growth
89 92 87 5
Safety
Safety
4 4 1 8
Sentiment
51 27 20 20
360° View
360° View
27 23 8 4
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
93 87 93 87
Opinions Change
77 28 17 50
Pro Holdings
n/a 38 47 8
Market Pulse
13 1 3 11
Sentiment
51 27 20 20
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
20 22 41 56
Growth
89 92 87 5
Safety Safety
4 4 1 8
Combined
14 26 26 4
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
8 1 100 68
Price vs. Earnings (P/E)
3 5 16 34
Price vs. Book (P/B)
100 100 100 100
Dividend Yield
1 1 1 1
Value
20 22 41 56
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
98 98 100 28
Profit Growth
85 51 67 28
Capital Growth
26 83 31 16
Stock Returns
95 88 60 14
Growth
89 92 87 5
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
1 1 1 3
Refinancing
25 21 1 52
Liquidity
19 19 19 17
Safety Safety
4 4 1 8

Similar Stocks

Discover high‑ranked alternatives to MedinCell and broaden your portfolio horizons.

Rubis

ENXTPA:RUI
Country: France
Industry: Gas Utilities
Size: Medium
Full Stock Analysis

Synergie

ENXTPA:SDG
Country: France
Industry: HR- & Employment Services
Size: Medium
Full Stock Analysis

Perrigo

NYSE:PRGO
Country: Ireland
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt.

BUSE:RICHTER
Country: Hungary
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.